CORRECTED: ABI Q3 Revenues Up 19 Percent, But Company Still Cautious About Future | GenomeWeb

This article has been corrected from a previous version, in which Applied Biosystems' president Michael Hunkapiller was referred to as the CEO, and in which a comment by Dr. Hunkapiller regarding sales of 3000 vs. 4000 series mass spectrometers was incorrectly reported as referring to DNA Sequencers. GenomeWeb regrets this inaccuracy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.